Discovery Laboratories, Inc.

WARRINGTON, Pa., May 15, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced that it has completed its previously announced public offering to sell an aggregate of 9.5 million shares of its common stock under Discovery Labs' previously filed registration statement that was declared effective by ... read more

WARRINGTON, Pa., May 10, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced that it has priced an underwritten public offering of 9.5 million shares of its common stock, at a price to the public of $1.50 per share for gross proceeds of $14.25 million. ... read more

WARRINGTON, Pa., May 9, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced that it is offering to sell shares of its common stock in an underwritten public offering. The Company also expects to grant the underwriter a 30-day option to purchase additional shares of common stock ... read more

WARRINGTON, Pa., May 7, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today reports financial results for the first quarter ended March 31, 2013 and also provides certain program updates. Selected operational updates: -- ... read more

WARRINGTON, Pa., May 1, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the release of two peer-reviewed publications related to AFECTAIR(®), the Company's proprietary aerosol-conducting airway connector designed with the goal ... read more

WARRINGTON, Pa., April 15, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the U.S. Food and Drug Administration (FDA) has requested clarification and provided recommendations regarding the recently-updated product specifications for SURFAXIN(®). ... read more

WARRINGTON, Pa., March 29, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the release of two peer-reviewed publications related to SURFAXIN(®) (lucinactant) Intratracheal Suspension. SURFAXIN, currently the only FDA approved synthetic ... read more

WARRINGTON, Pa., March 13, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today reports financial results for the fourth quarter ended December 31, 2012 and also provides certain program updates. The Company will host a ... read more

WARRINGTON, Pa., March 6, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO) will report fourth quarter 2012 results on Wednesday, March 13, 2013 before the open of the U.S. financial markets. The Company will also host a conference call at 10:00 a.m. ET that same day ... read more

WARRINGTON, Pa., Feb. 13, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that it has entered into a secured loan facility with Deerfield Management Company, L.P. (Deerfield) for up to $30.0 ... read more

WARRINGTON, Pa., Jan. 4, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced changes to its board of directors and appointed a new Chief Executive Officer (CEO). The following changes are effective immediately: ... read more

WARRINGTON, Pa., Jan. 3, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced it has initiated the launch of its AFECTAIR(®) airway connector for infants receiving aerosolized medication in neonatal or ... read more

WARRINGTON, Pa., Dec. 4, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced the release of data from a new pharmacoeconomic analysis demonstrating that the previously-reported reduced rate of reintubation in preterm infants treated with SURFAXIN(® )may also result in an average potential hospital cost savings of $389,247 per ... read more

WARRINGTON, Pa., Nov. 28, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced it will present both SURFAXIN(®) and AFECTAIR(®) data at the 2012 Hot Topics in Neonatology Annual Meeting being held December 3-4 in Washington D.C. Hot Topics in Neonatology is an internationally recognized medical meeting dedicated ... read more